Lexology February 13, 2025
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second round of negotiations as part of the Medicare Drug Price Negotiation Program (the Negotiation Program), but the Trump administration and a Republican majority in Congress leaves the future of the Negotiation Program uncertain. As outlined in the Q2 2024 edition of our Mintz IRA Update, the second round of negotiations will take place throughout 2025, and the resulting maximum fair prices (MFPs) for the next 15 drugs are slated to become effective on January 1, 2027. In this article, we explore the recent changes made by CMS to the Negotiation Program following the first round of negotiations; manufacturers’ reactions to the MFP...
Today's Sponsors
Today's Sponsor